What does Leuprolide do?

Leuprolide is described in the source as a synthetic GnRH agonist peptide. It is used in FDA-approved contexts involving hormone suppression, including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.

How does Leuprolide work?

It first activates pituitary GnRH receptors strongly enough to cause a short-lived rise in LH, FSH, and gonadal hormones. With ongoing exposure, pituitary GnRH signaling becomes desensitized, leading to reduced testosterone or estrogen production. The source notes that this early hormone flare can matter clinically in some conditions.

Is Leuprolide FDA approved?

Yes. The supplied source lists Leuprolide as FDA approved for multiple indications.

What side effects are reported for Leuprolide?

The source lists hot flashes, injection-site reactions, headache, fatigue, depression and other mood changes, bone thinning with longer use, tumor flare reaction, and cardiovascular risks. These are evidence-captured adverse-effect topics, not a complete safety profile.

What is the typical dose of Leuprolide?

The source reports formulation-dependent dosing, with a community range from 1 mg daily to 45 mg every 6 months and a research-labeling example of a 7.5 mg monthly depot. This profile does not provide personal dosing instructions.

Hormonal FDA Approved - approved for specific uses

Leuprolide

Also known as: Lupron, Eligard, Leuprorelin

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

FDA-approved synthetic GnRH agonist peptide for hormone-suppression indications

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

Variable - depends on formulation

Intramuscular or subcutaneous depot injection

Researched for

Prostate cancer, endometriosis, hormone suppression

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

Synthetic GnRH also known by aliases including Lupron, Eligard, and Leuprorelin.
Source lists FDA-approved use across multiple hormone-related indications.
Administration and frequency depend on formulation, including daily and depot schedules.
Reported research areas include prostate cancer, endometriosis, and hormone suppression.
Adverse effects largely relate to injection reactions, hormone suppression, and flare phenomena.

How it's thought to work

Leuprolide is reported to act as a high-potency at pituitary GnRH receptors. Initial receptor activation can briefly increase LH, FSH, and sex hormones, but sustained exposure desensitizes the pituitary GnRH response and suppresses downstream gonadal hormone production. The source links this hormone-lowering effect to use in androgen- or estrogen-sensitive conditions and notes that the early flare can be clinically relevant.

What the research shows

Where the research stands

The supplied evidence frames Leuprolide as a long-established FDA-approved GnRH with clinical use rather than as an exploratory research . It reports approval dating to 1989 and describes evidence in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The same source emphasizes that its benefits are tied to reversible suppression of sex-hormone production, while many important adverse effects arise from that low-hormone state, including hot flashes and bone-density concerns with longer exposure.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA Approved - Multiple indications FDA Approved

Typical dosing

CommunityCommunity dataset

Variable - depends on formulation

Daily, monthly, or every 3-6 months

Range: 1 mg daily to 45 mg every 6 months

Community-sourced dosing varies by formulation and indication; this row is informational and is not dosing guidance.

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

7.5mg monthly depot

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Months to years depending on indication
Administration: Intramuscular or subcutaneous depot injection

Timing & administration

Best time to take

Morning or as directed

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The source does not establish a universal best time; timing is described as protocol-dependent, with consistency treated as more important than a specific clock time.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Hot flashes
Injection site reactions
Headache
Fatigue
Depression and mood changes
Bone thinning
Tumor flare reaction
Cardiovascular risks

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Leuprolide

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Leuprolide

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions